These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 21745592)

  • 21. Polaprezinc attenuates liver fibrosis in a mouse model of non-alcoholic steatohepatitis.
    Sugino H; Kumagai N; Watanabe S; Toda K; Takeuchi O; Tsunematsu S; Morinaga S; Tsuchimoto K
    J Gastroenterol Hepatol; 2008 Dec; 23(12):1909-16. PubMed ID: 18422963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue.
    Kudo H; Yata Y; Takahara T; Kawai K; Nakayama Y; Kanayama M; Oya T; Morita S; Sasahara M; Mann DA; Sugiyama T
    Liver Int; 2009 Aug; 29(7):988-96. PubMed ID: 19386026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatic lipid profile in mice fed a choline-deficient, low-methionine diet resembles human non-alcoholic fatty liver disease.
    Haberl EM; Pohl R; Rein-Fischboeck L; Höring M; Krautbauer S; Liebisch G; Buechler C
    Lipids Health Dis; 2020 Dec; 19(1):250. PubMed ID: 33298075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease.
    Ganji SH; Kukes GD; Lambrecht N; Kashyap ML; Kamanna VS
    Am J Physiol Gastrointest Liver Physiol; 2014 Feb; 306(4):G320-7. PubMed ID: 24356885
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting cholesterol at different levels in the mevalonate pathway protects fatty liver against ischemia-reperfusion injury.
    Llacuna L; Fernández A; Montfort CV; Matías N; Martínez L; Caballero F; Rimola A; Elena M; Morales A; Fernández-Checa JC; García-Ruiz C
    J Hepatol; 2011 May; 54(5):1002-10. PubMed ID: 21145825
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activation of peroxisome proliferator-activated receptor alpha by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation.
    Larter CZ; Yeh MM; Cheng J; Williams J; Brown S; dela Pena A; Bell-Anderson KS; Farrell GC
    J Gastroenterol Hepatol; 2008 Feb; 23(2):267-75. PubMed ID: 17868330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hydrogenated phosphatidylcholine supplementation reduces hepatic lipid levels in mice fed a high-fat diet.
    Tandy S; Chung RW; Kamili A; Wat E; Weir JM; Meikle PJ; Cohn JS
    Atherosclerosis; 2010 Nov; 213(1):142-7. PubMed ID: 20832797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolomics-based search for therapeutic agents for non-alcoholic steatohepatitis.
    Terashima Y; Nishiumi S; Minami A; Kawano Y; Hoshi N; Azuma T; Yoshida M
    Arch Biochem Biophys; 2014 Aug; 555-556():55-65. PubMed ID: 24857839
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Betaine supplementation prevents fatty liver induced by a high-fat diet: effects on one-carbon metabolism.
    Deminice R; da Silva RP; Lamarre SG; Kelly KB; Jacobs RL; Brosnan ME; Brosnan JT
    Amino Acids; 2015 Apr; 47(4):839-46. PubMed ID: 25577261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of dietary supplementation with betaine on a nonalcoholic steatohepatitis (NASH) mouse model.
    Kawakami S; Han KH; Nakamura Y; Shimada K; Kitano T; Aritsuka T; Nagura T; Ohba K; Nakamura K; Fukushima M
    J Nutr Sci Vitaminol (Tokyo); 2012; 58(5):371-5. PubMed ID: 23327974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel inhibitor of stearoyl-CoA desaturase-1 attenuates hepatic lipid accumulation, liver injury and inflammation in model of nonalcoholic steatohepatitis.
    Kurikawa N; Takagi T; Wakimoto S; Uto Y; Terashima H; Kono K; Ogata T; Ohsumi J
    Biol Pharm Bull; 2013; 36(2):259-67. PubMed ID: 23370355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dietary modification dampens liver inflammation and fibrosis in obesity-related fatty liver disease.
    Larter CZ; Yeh MM; Haigh WG; Van Rooyen DM; Brooling J; Heydet D; Nolan CJ; Teoh NC; Farrell GC
    Obesity (Silver Spring); 2013 Jun; 21(6):1189-99. PubMed ID: 23666886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice.
    Zheng S; Hoos L; Cook J; Tetzloff G; Davis H; van Heek M; Hwa JJ
    Eur J Pharmacol; 2008 Apr; 584(1):118-24. PubMed ID: 18329014
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Ethanol Extract from Lonicera japonica Thunb. Regresses Nonalcoholic Steatohepatitis in a Methionine- and Choline-Deficient Diet-Fed Animal Model.
    Tzeng TF; Tzeng YC; Cheng YJ; Liou SS; Liu IM
    Nutrients; 2015 Oct; 7(10):8670-84. PubMed ID: 26506376
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin-6 is associated with liver lipid homeostasis but not with cell death in experimental hepatic steatosis.
    Sánchez-Garrido MA; Chico Y; González R; Ranchal I; González-Rubio S; Hidalgo AB; Díaz-López C; Costán G; Padillo FJ; De la Mata M; Ochoa B; Muntané J
    Innate Immun; 2009 Dec; 15(6):337-49. PubMed ID: 19710104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet.
    Koppe SW; Sahai A; Malladi P; Whitington PF; Green RM
    J Hepatol; 2004 Oct; 41(4):592-8. PubMed ID: 15464239
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transcriptomic and epigenetic changes in early liver steatosis associated to obesity: effect of dietary methyl donor supplementation.
    Cordero P; Campion J; Milagro FI; Martinez JA
    Mol Genet Metab; 2013 Nov; 110(3):388-95. PubMed ID: 24084163
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dietary creatine supplementation lowers hepatic triacylglycerol by increasing lipoprotein secretion in rats fed high-fat diet.
    da Silva RP; Leonard KA; Jacobs RL
    J Nutr Biochem; 2017 Dec; 50():46-53. PubMed ID: 29031242
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipid-lowering agents inhibit hepatic steatosis in a non-alcoholic steatohepatitis-derived hepatocellular carcinoma mouse model.
    Orime K; Shirakawa J; Togashi Y; Tajima K; Inoue H; Nagashima Y; Terauchi Y
    Eur J Pharmacol; 2016 Feb; 772():22-32. PubMed ID: 26724391
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis.
    Asano T; Watanabe K; Kubota N; Gunji T; Omata M; Kadowaki T; Ohnishi S
    J Gastroenterol Hepatol; 2009 Oct; 24(10):1669-76. PubMed ID: 19788607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.